Sponsored by Saxo


Good morning everyone. On Stockhead today, Josh Chiat looks at what’s moving and shaking iron ore and coal markets right now, there’s been another giant IPO failure in Honkers, and an Aussie defence stock that might be seriously undervalued – according to experts. Not us.

Here’s the other stuff you need before you get stuck in.



Gold: US$2,390.60 (+0.47%)

Silver: US$28.68 (+1.58%)

Nickel (3mth): US$19,469.00/t (+4.90%)

Copper (3mth): US$9,707.07/t (+2.55%)

Oil (WTI): US$83.14 (+0.50%)

Oil (Brent): US$87.29 (+0.21%)

Iron 62pc Fe: US$108.25/t (+0.28%)

AUD/USD: 0.6413 (-0.13%)

Bitcoin: US$64,827.10 (-0.22%)



For once, it actually came in close to 10am:



Swipe or scroll to reveal full table. Click headings to sort:

Wordpress Table Plugin


Augustus Minerals (ASX:AUG) says it may have have its copper targets at Tiberius and Claudius after releasing its rock chip assays. Assays include a ripping 17.8% copper and 282g/t silver at Tiberius, which is currently 3m wide and 200m along strike. At Claudius, 11km to the south, results have outlined a number of parallel zones over 100m by 300m at grades of up to 6.6% Cu and 86g/t Ag.

Rincon Resources (ASX:RCR) jumped after reporting news of a string of new gravity targets to prioritise for drilling around its West Arunta ground. Those four new prospects are called K1, K2, Sheoak and Avalon, with three existing targets in the Pokali iron-oxide copper-gold prospect at Arrow, Dune and Surprise also enhanced by the ground gravity surveys. A program of works application has been submitted with WA’s mines regulator to enable RC drilling at all targets.

James Bay Minerals (ASX:JBY) says a field program is expected to start in the next four weeks to follow up airborne surveys, data from neighbouring properties and desktop studies completed since last year’s listing. “Our focus now is on ensuring that we target low-hanging fruit across all areas of the La Grande Project. This will ensure that we deploy capital efficiently on well-established targets,” said JBY’s executive director, Andrew Dornan.

And Osteopore (ASX:OSX) popped big on news of the start of first-in-human clinical trials for knee preservation in Singapore, where the medtech specialises in “3D-printed biomimetic and bioresorbable” implants. Its first patient was treated for knee preservation with Heparan Sulphate 3 (HS3) and aXOpore via a High Tibial Osteotomy (HTO) at the National University Hospital (NUH), Singapore.”



Swipe or scroll to reveal full table. Click headings to sort

Wordpress Table Plugin